Attention-Deficit / Hyperactivity Disorder
- Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental, chronic disorder involving a persistent pattern of inattention and/or hyperactivity/impulsivity that interferes with functioning or development.
- ADHD is classified under the Neurodevelopmental Disorders section of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).
- The DSM-5 has an extensive, but not exhaustive, list of criteria for ADHD. For these detailed criteria, please see the DSM-5 itself.
- The criteria-based diagnosis requires meeting of inattention and/or hyperactivity-impulsivity criteria, onset before age 12, occurrence in two or more settings, and resulting impairment in functioning.
- Population studies suggest that ADHD occurs in most cultures in 5% of children and 4.4% of adults.
- More frequent in males than females, with ratio of 2:1 in children and 1.6:1 in adults
- Females may be more likely to present primarily with inattentive features.
- Risk factors:
- Temperament (e.g., reduced behavioral inhibition and effortful control, increased negative emotionality and novelty-seeking)
- Environmental (e.g., very low birth weight: < 1500g, in utero exposures)
- Genetic: substantial heritability
- ADHD is a multifaceted disorder which varies greatly in symptom type and severity.
- Along with inattention, hyperactivity, and impulsivity, difficulties with emotion regulation, cognitive deficits, and multiple comorbidities are common (e.g., learning disorders, oppositional defiant disorder).
- ADHD is often a lifelong disorder, with 85% of adolescents and 50% of adults exhibiting residual symptoms.
- Poor social/interpersonal functioning and negative self-attitude are common, along with poor frustration tolerance and irritability.
- ADHD is associated with increased risk for later depression and suicide attempts.
Tests and Procedures
Tests and Procedures
- ADHD is a clinical diagnosis based on developmental history, clinical interview regarding symptoms/impairment, and objective ratings of inattention and/or hyperactivity/impulsivity across multiple settings, with multiple informants (e.g., parents, teachers).
- When assessing adults, collateral and developmental data is needed to document developmental onset.
- There is no diagnostic laboratory test or imaging modality to diagnose ADHD.
- However, etiology-specific tests, such as TSH or serum lead levels may be helpful when hyperthyroidism or lead poisoning are suspected by history or examination.
- In the pediatric population, common ADHD screening measures include:
- Broad-band measures of psychopathology
- e.g., the Child Behavior Checklist, the Behavior Assessment Scale for Children
- Narrow-band measures that are specific to ADHD and common comorbidities
- e.g., the Vanderbilt ADHD Diagnostic Parent Rating Scale, the SNAP Parent and Teacher Rating Scales, the Disruptive Behavior Disorder Parent and Teacher Rating Scales
- Broad-band measures of psychopathology
- For the adult population, there are a few ADHD-specific screening tools available for self and informant ratings:
- e.g., the Barkley Adult ADHD Rating Scale–IV, the Adult ADHD Self-Report Scale, the Conners Adult ADHD Rating Scale (CAARS)
- Some measures focus on assessment of childhood ADHD symptoms in patients who present as adults.
- e.g., the Wender Utah Rating Scale
- Some patients may benefit from psychological testing to clarify whether cognitive deficits should be addressed in treatment.
- e.g., to assess for low intelligence, executive dysfunction, and learning disabilities
- Computerized tests show modest correlations with parent and teacher ratings and do not detect inattention unique to ADHD.
- e.g., the CPT-II
- Oppositional defiant disorder
- Conduct disorder
- Anxiety disorders
- Depressive/mood disorders
- Substance use disorders
- Developmental disorders (e.g., autism spectrum disorders)
- Learning disorders or intellectual limitations
- Sleep disorders
- Obsessive-compulsive disorder
- Epilepsy and other neurological disorders
- Elimination disorders (e.g., enuresis, encopresis)
- A combination of stimulant medication and behavior therapy is first-line treatment.
- Treatment may involve home-, clinic-, and school-based efforts.
- Psychoeducation is useful to increase parent, teacher, and self-knowledge about ADHD symptoms and effects on behavior and emotions.
- Family involvement and control of behaviors (e.g. noncompliance, oppositionality, rule-breaking) are beneficial.
- Most youths and adults with ADHD respond favorably to psychostimulants (e.g., derivatives of methyphenidate and amphetamine).
- Efficacy in preschoolers is more modest.
- Common adverse effects include appetite decrease, weight loss, insomnia, and headache.
- These may improve with dose adjustment or switching to another stimulant.
- Coexisting substance use disorders may increase the risk for diversion of stimulants.
- Osmotic delivery systems (e.g., Concerta) may reduce inappropriate use.
- For young patients and any patients with difficulties swallowing pills, liquid preparations are available.
- e.g., dextroamphetamine, ProCentra, methylphenidate HCl, Quillivant
- Nonstimulant medications have more modest effects and typically take longer to produce therapeutic responses.
- e.g., atomoxetine, guanfacine, and bupropion
- These may be useful when stimulants side effects are intolerable, or as adjunctive treatment.
- To optimize medication treatment, pre- and post-treatment parent and teacher ratings are recommended until adequate dosing is achieved with minimal adverse effects.
- Behavior therapy (i.e., parent management training) is effective as front-line treatment for mild ADHD and recommended as an adjunctive treatment for moderate-to-severe ADHD.
- Comorbid disruptive behavior (e.g., ODD) is also an indication for behavior therapy.
- Cognitive behavioral therapy (CBT) may be appropriate in older children, adolescents, and adults with comorbid internalizing symptoms (e.g., anxiety, depression).
- CBT in older adolescents and adults on stable stimulant doses may help manage residual symptoms of ADHD (e.g., disorganization, time management).
- Consulting with schools about behavior management and supports is recommended.
- ADHD is a chronic disease with early onset and frequent progression into adulthood.
- Engagement in prosocial, healthy activities is recommended (e.g., sports, social activities, exercise).
- Vitamins, dietary supplements, and other alternative/complementary approaches lack scientific evidence of effectiveness.
WHEN TO REFER
- Pediatricians and other primary care physicians manage the majority of patients with ADHD.
- Pediatricians are well-positioned to diagnose and treat uncomplicated ADHD.
- ADHD without hyperactivity/impulsivity may be more difficult to detect.
- ADHD over diagnosis and over treatment may be common in some community settings.
- Seek psychiatrist consultation if the patient exhibits unusual reactions to stimulants or fails three trials of stimulant medications.
- Patients with preexisting cardiac disease should undergo cardiologic evaluation prior to initiating a stimulant medication.
- Consider referring to a child psychologist or psychiatrist when multiple comorbid conditions.
- e.g., learning issues, social problems, internalizing/externalizing disorders
- The need for ongoing behavior therapy can be determined by a child’s level of functional impairment and co-occurring behavioral difficulties.
- Annual medication-free periods are recommended to reassess the need for medication and optimize dosing.
- ADHD is associated with other psychiatric disorders, notably disruptive behavior problems, internalizing disorders, and later substance use problems.
- These will need to be addressed during treatment.
- All ADHD subtypes in childhood predict adolescent depression/dysthymia and suicide attempts, underlining the need for ongoing treatment across development.
- Attention and impulsivity/hyperactivity are dimensional in nature.
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Adler LA, Dirks B, Deas P, et al. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study. BMC Psychiatry. 2013;13(1):253. [PMID:24106804]
- Amador-Campos JA, Gómez-Benito J, Ramos-Quiroga JA. The Conners' Adult ADHD Rating Scales--Short Self-Report and Observer Forms: Psychometric Properties of the Catalan Version. J Atten Disord. 2012. [PMID:22771453]
- Becker SP, Langberg JM, Luebbe AM, et al. Sluggish Cognitive Tempo is Associated With Academic Functioning and Internalizing Symptoms in College Students With and Without Attention-Deficit/Hyperactivity Disorder. J Clin Psychol. 2013. [PMID:24114716]
- Chronis-Tuscano A, Molina BS, Pelham WE, et al. Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2010;67(10):1044-51. [PMID:20921120]
- Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl):26S-49S. [PMID:11833633]
- Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-23. [PMID:16585449]
- Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65(1):46-54. [PMID:19006789]
- McGee RA, Clark SE, Symons DK. Does the Conners' Continuous Performance Test aid in ADHD diagnosis? J Abnorm Child Psychol. 2000;28(5):415-24. [PMID:11100916]
- Riccio CA, Reynolds CR. Continuous performance tests are sensitive to ADHD in adults but lack specificity. A review and critique for differential diagnosis. Ann N Y Acad Sci. 2001;931:113-39. [PMID:11462737]
- Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(6):885-90. [PMID:8494063]
- Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5(4):189-202. [PMID:11967475]
Attention-Deficit / Hyperactivity Disorder is a sample topic from the Johns Hopkins Psychiatry Guide.
To view other topics, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Complete Product Information.
Last updated: November 6, 2014
Burkey, Matthew , and Carisa Perry-Parrish. "Attention-Deficit / Hyperactivity Disorder." Johns Hopkins Psychiatry Guide, 2014. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787036/all/Attention_Deficit___Hyperactivity_Disorder.
Burkey M, Perry-Parrish C. Attention-Deficit / Hyperactivity Disorder. Johns Hopkins Psychiatry Guide. 2014. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787036/all/Attention_Deficit___Hyperactivity_Disorder. Accessed March 26, 2023.
Burkey, M., & Perry-Parrish, C. (2014). Attention-Deficit / Hyperactivity Disorder. In Johns Hopkins Psychiatry Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787036/all/Attention_Deficit___Hyperactivity_Disorder
Burkey M, Perry-Parrish C. Attention-Deficit / Hyperactivity Disorder [Internet]. In: Johns Hopkins Psychiatry Guide. ; 2014. [cited 2023 March 26]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787036/all/Attention_Deficit___Hyperactivity_Disorder.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Attention-Deficit / Hyperactivity Disorder ID - 787036 A1 - Burkey,Matthew ,M.D. AU - Perry-Parrish,Carisa,Ph.D. Y1 - 2014/11/06/ BT - Johns Hopkins Psychiatry Guide UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787036/all/Attention_Deficit___Hyperactivity_Disorder DB - Johns Hopkins Guides DP - Unbound Medicine ER -